Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 261-448-2 | CAS number: 58798-47-3
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 15 April to 22 May 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- Buehler test
- Justification for non-LLNA method:
- Method was not available
Test material
- Reference substance name:
- 2-[[(4-methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium methyl sulphate
- EC Number:
- 258-946-7
- EC Name:
- 2-[[(4-methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium methyl sulphate
- Cas Number:
- 54060-92-3
- Molecular formula:
- C20H24N3O.CH3O4S C21H27N3O5S
- IUPAC Name:
- 2-{[2-(4-methoxyphenyl)-2-methylhydrazin-1-ylidene]methyl}-1,3,3-trimethyl-3H-indol-1-ium methyl sulfate
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): Astrazon Goldgelb GL-E 200% micro
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- other: pirbright-white
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann, Gartenstraße 27, 33178 Borchen, Germany
- Age at study initiation: -
- Weight at study initiation: 339 g to 414 g
- Housing: 5 animals/group
- Diet (ad libitum): ssniff Ms-H V2233
- Water (ad libitum): tap water
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17 to 23
- Humidity (%): 30 to 70
- Air changes (per hr): -
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 15 April To: 22 May 1998
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- water
- Concentration / amount:
- Induction and Challenge: 0.5 g moistened with 0.5 mL deionized water
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- water
- Concentration / amount:
- Induction and Challenge: 0.5 g moistened with 0.5 mL deionized water
- No. of animals per dose:
- Determination of primary non-irritant concentration: 3
Control group: 10
Treatment group 20 - Details on study design:
- RANGE FINDING TESTS:
100 %, 20 %, 4 % (1000, 200, 40 mg/mL)
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 3
- Exposure period: 6 hours occlusive
- Test groups: 1000 mg/mL (0.5 mL) in deionized water
- Control group: 0.5 mL deionized water
- Frequency of applications: once/week
- Duration: Day 1 to 15
- Site: left flank
- Concentrations: 100 %
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: Day 29
- Exposure period: 6 hours
- Test groups: 1000 mg/mL (0.5 mL) in deionized water
- Control group: 1000 mg/mL (0.5 mL) in deionized water
- Site: right flank
- Concentrations: 100 %
- Evaluation (hr after challenge): 24 and 48 hours after removal of patches - Challenge controls:
- NA
- Positive control substance(s):
- yes
- Remarks:
- alpha-hexyl cinnamic aldehyde in PEG 400
Results and discussion
- Positive control results:
- 30% positive = valid
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 1000 mg/mL
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- skin surface orange discolored
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 1000 mg/mL. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: skin surface orange discolored.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 1000 mg/mL
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- skin surface orange discolored
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 1000 mg/mL. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: skin surface orange discolored.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 1000 mg/mL
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- skin surface orange discolored
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 1000 mg/mL. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: skin surface orange discolored.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 1000 mg/mL
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- skin surface orange discolored
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 1000 mg/mL. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: skin surface orange discolored.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 20 %
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: positive control. Dose level: 20 %. No with. + reactions: 2.0. Total no. in groups: 20.0.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 20 %
- No. with + reactions:
- 1
- Total no. in group:
- 20
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: positive control. Dose level: 20 %. No with. + reactions: 1.0. Total no. in groups: 20.0.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 20 %
- No. with + reactions:
- 6
- Total no. in group:
- 20
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: positive control. Dose level: 20 %. No with. + reactions: 6.0. Total no. in groups: 20.0.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 20 %
- No. with + reactions:
- 5
- Total no. in group:
- 20
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: positive control. Dose level: 20 %. No with. + reactions: 5.0. Total no. in groups: 20.0.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Astrazon Goldgelb GL-E 200% micro showed no sensitizing properties in the Buehler test
- Executive summary:
Testing for sensitizing properties of Astrazon Goldgelb GL-E 200% was performed in female guinea pigs according to the method of BUEHLER.
Dermal induction was performed using 100 % Astrazon Goldgelb GL-E 200% moistened with deionized water.
Challenge treatment were carried out with 100 % Astrazon Goldgelb GL-E 200% moistened with deionized water.
The validity of the test system is confirmed by the periodically conducted positive control test using alpha-hexyl cinnamic aldehyde for the BUEHLER test (report number 98.0419, dated June 26, 1998; Hoechst Marion Roussel Deutschland GmbH, Drug Safety).
Under the conditions of the present study, none of twenty animals of the treatment group showed a positive skin response after the challenge procedure.
Based on the results of this study Astrazon Goldgelb GL-E 200% showed no evidence for sensitizing properties.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
